ClinicalTrials.gg
CompletedNCT05467540SPARTAUpdated Nov 28, 2025Results posted

Spinery® A Novel Radio-Frequency Tumor Ablation Device for Spine Metastatic Tumors

An interventional study of Spinery System in Vertebral Metastasis, sponsored by Axon srl. Completed at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Axon srl · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 352 studies in Neoplasm Metastasis with a site in Italy — 71 open to participants now, 115 under way, 40 of them phase 3. Neoplasm Metastasis · Italy.

Enrollment
245th of 297
52 · median 205
Started
2022
with 26 others
No phase
26 of 352
11 open now
Registered
274th of 352
by date

Among the 352 studies in Neoplasm Metastasis with a site in Italy, this one is the 245th largest by enrollment of the 297 interventional ones that give a count, is one of 27 that started in 2022, is one of 26 with no phase, and was the 274th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

71 of the 352 studies in Neoplasm Metastasis with a site in Italy are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 352 studies in Neoplasm Metastasis with a site in Italy, or all of them as a file.
02

Study summary

The SPARTA study (Spinery® Radiofrequency Ablation Device Study) is a prospective, multicenter, single-arm clinical investigation designed to evaluate the safety, performance, and efficacy of the Spinery® RF Generator and its sterile single-use accessories for the palliative treatment of painful bone metastases.

Adult patients with metastatic lesions involving the vertebral bodies, sacrum, iliac crest, or peri-acetabulum who were not candidates for, or had failed, standard therapies underwent percutaneous radiofrequency ablation with the investigational device.

A total of 52 participants were enrolled across five Italian centers and were assessed at baseline, post-procedure, and during follow-up visits at 1, 3, and 12 months.

Endpoints include evaluation of pain reduction, quality of life, usability, and procedural safety.

Read the detailed description

Bone metastases are a frequent cause of pain and disability in patients with advanced cancer, often leading to impaired mobility and reduced quality of life. Conventional treatments such as systemic analgesics, radiotherapy, or chemotherapy may not always achieve adequate symptom control, particularly in patients with recurrent or resistant disease.

Radiofrequency (RF) ablation has emerged as a minimally invasive, image-guided procedure that induces controlled thermal necrosis within metastatic lesions, potentially reducing pain by interrupting nociceptive pathways and stabilizing the affected bone.

The SPARTA study was designed to collect clinical data on the Spinery® RF Generator and its sterile single-use accessories, a bipolar/monopolar RF ablation technology intended for percutaneous use in bone metastases.

This clinical investigation follows a prospective, multicenter, single-arm design without a control group; data are compared with published evidence available in the literature to contextualize safety and performance outcomes.

A total of 52 patients were enrolled across five Italian centers. Eligible participants were adults with painful metastatic bone tumors located in the thoracic or lumbar vertebrae, sacrum, iliac crest, or peri-acetabulum.

Following informed consent and baseline assessments, each patient underwent image-guided RF ablation using the Spinery® device. The procedure allowed the treating physician to select monopolar or bipolar cooled electrodes according to lesion size and location.

Participants were monitored within 24 hours post-procedure and followed at 1, 3, and 12 months after treatment.

Study assessments include:

  • Pain evaluation using the Brief Pain Inventory (BPI)
  • Quality of life assessment using the EQ-5D-5L questionnaire
  • Functional performance using the Karnofsky Performance Scale
  • Documentation of concomitant analgesic use and adverse events

The primary objectives are:

  1. To evaluate short-term pain reduction at 3 months following treatment, as measured by changes in the BPI "worst pain" score.
  2. To evaluate procedural safety, defined as the percentage of procedures completed without device-related adverse events, including nerve injury.

The secondary objectives are:

  • To assess long-term pain reduction at 12 months.
  • To evaluate usability and procedural performance (technical and procedural success without product-specialist intervention).
  • To monitor quality-of-life and functional outcomes over the follow-up period.

This clinical investigation is conducted in compliance with ethical principles of Good Clinical Practice and applicable regulatory requirements.

03

Conditions studied

  • Vertebral Metastasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with painful malignant lesions involving bone;
  • Patients, candidates to standard therapy, in which the RF ablation can be performed in combination with the Standard Therapy in accordance with the Investigator's indications;
  • Patients who have failed, not candidates or refuse Standard Therapy (chemotherapy or radiotherapy);
  • Patients with metastatic tumor size compatible with the expected ablation dimensions as reported for SPINERY devices in the IFU;
  • Patients with localized pain resulting from not more than two sites of symptomatic metastatic disease
  • Patients that do not have evidence of impending fracture
  • Patients with metastatic lesions targeted for treatment located in the thoracic and/or lumbar vertebral body(ies), peri-acetabulum, iliac crest, and/or sacrum - no restrictions on location of lesion;
  • Patients with BPI-Report worst pain score ≥4/10 at the target treatment site within the past 24 hours
  • Patients with score ≥ 40 at enrollment
  • Patients willing and able to provide a signed and dated , comply with the study plan, follow up visits and phone calls
  • Patients at least 18 years old at the time of informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients implanted with heart pacemaker or other implanted electronic device
  • Patients with previous mechanical bone stabilization in the vertebral body to be treated
  • Use of SPINERY in vertebral body levels C1-C7
  • Multiple myeloma, solitary plasmacytoma, or primary malignant lesions in the index vertebra or bone.
  • Active or incompletely treated local infection at the planned treatment site(s) and/or systemic infection.
  • Planned treatment site(s) accompanied by objective evidence of secondary radiculopathy or neurologic compromise.
  • Planned treatment site(s) associated with spinal cord compression or canal compromise requiring decompression.
  • Fractures due to prostatic cancer or other osteoblastic to the spine. Metastatic lesions originating in the prostate that are osteolytic or of mixed origin are eligible for the study.
  • Pregnant, breastfeeding, or plan to become pregnant during the study duration.
  • Concurrent participation in another clinical study that may add additional safety risks and/or confound study results.
  • Any condition that would interfere with the subject's ability to comply with study instructions or might confound the study interpretation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Spinery® RF Ablation System Arm

    Participants in this single-arm study underwent percutaneous radiofrequency ablation of painful bone metastases using the Spinery System, consisting of the Spinery® RF Generator, the sterile single-use Spinery® Kit, and the sterile single-use Spinery® Cooling Connection. The procedure was performed according to the study protocol, with follow-up visits scheduled at 1, 3, and 12 months to assess pain reduction, safety, usability, and quality of life.

    Device: Spinery System

Interventions

  • DeviceSpinery System

    Radiofrequency ablation of bone metastases performed with the Spinery System, a radiofrequency generator with dedicated sterile, single-use accessories (electrode kit and cooling connection).

    Also known as: Spinery® RF Generator, the sterile single-use Spinery® Kit, and the sterile single-use Spinery® Cooling Connection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires

    Pain severity and health-related quality of life were evaluated using two validated questionnaires: * Brief Pain Inventory (BPI): Participants rated their worst pain in the last 24 hours for each treated lesion site (thoracic, lumbar, peri-acetabulum, iliac crest, sacrum) on an 11-point numeric scale from 0 (no pain) to 10 (pain as bad as you can imagine). Higher scores indicate worse pain. The change in BPI Worst Pain Score was calculated as the average reduction from baseline to the 3-month visit. * EQ-5D-5L: Participants reported their overall health status across five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels of severity. Responses were converted into a utility index ranging from -0.594 (worst health state) to 1.000 (best health state), where higher scores indicate better quality of life. The EQ-5D-5L visual analogue scale (VAS) ranges from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Baseline and 3-month follow-up

  2. Number and Percentage of Participants Who Successfully Completed the Spinery® RF Ablation Procedure

    The number and percentage of participants who successfully completed the Spinery® RF ablation procedure per protocol. Completion is defined as participants who underwent the full planned treatment without premature discontinuation or technical interruption. Results are expressed as the count and percentage of the total number of treated participants.

    Time frame: Post-Procedure (primary evaluation point)

07

Results

Posted Nov 28, 2025

Participant flow

Participants were recruited between July 2022 and Nov 2023 at 5 clinical sites. Eligible participants were adult who met all inclusion/exclusion criteria specified in the protocol. Recruitment followed standard informed consent procedures at each site.

BaseLine
Participant flow — BaseLine
MilestoneSpinery RF Ablation Treatment Group
Started51
Completed51
Not completed0
3-Month Follow-up
Participant flow — 3-Month Follow-up
MilestoneSpinery RF Ablation Treatment Group
Started51
Completed41
Not completed10
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up4
Withdrew: Death5
12-Month Follow-up
Participant flow — 12-Month Follow-up
MilestoneSpinery RF Ablation Treatment Group
Started41
Completed26
Not completed15
Withdrew: Lost to follow-up6
Withdrew: Death8
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires

Pain severity and health-related quality of life were evaluated using two validated questionnaires: * Brief Pain Inventory (BPI): Participants rated their worst pain in the last 24 hours for each treated lesion site (thoracic, lumbar, peri-acetabulum, iliac crest, sacrum) on an 11-point numeric scale from 0 (no pain) to 10 (pain as bad as you can imagine). Higher scores indicate worse pain. The change in BPI Worst Pain Score was calculated as the average reduction from baseline to the 3-month visit. * EQ-5D-5L: Participants reported their overall health status across five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels of severity. Responses were converted into a utility index ranging from -0.594 (worst health state) to 1.000 (best health state), where higher scores indicate better quality of life. The EQ-5D-5L visual analogue scale (VAS) ranges from 0 (worst imaginable health) to 100 (best imaginable health).

Time frame:
Baseline and 3-month follow-up
Reported as:
Mean · points on a numeric scale
Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires
points on a numeric scale3-Months Follow-up
Change in Worst Pain Score (BPI, 0-10 scale; higher = worse pain)3.4 ± 2.8
Change in Quality of Life (EQ-5D-5L VAS, 0-100 scale; higher = better health status)65.2 ± 19.0
PrimaryNumber and Percentage of Participants Who Successfully Completed the Spinery® RF Ablation Procedure

The number and percentage of participants who successfully completed the Spinery® RF ablation procedure per protocol. Completion is defined as participants who underwent the full planned treatment without premature discontinuation or technical interruption. Results are expressed as the count and percentage of the total number of treated participants.

Time frame:
Post-Procedure (primary evaluation point)
Reported as:
Count of participants · Participants
Number and Percentage of Participants Who Successfully Completed the Spinery® RF Ablation Procedure
ParticipantsPost-Procedure
Number and Percentage of Participants Who Successfully Completed the Spinery® RF Ablation Procedure51

Adverse events

Collected over Serious and Other (Not Including Serious) Adverse Events were assessed from the day of the Spinery® RF Ablation procedure through the 3-month follow-up visit. All-Cause Mortality was assessed from the day of the procedure through the 12-month follow-up visit.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants13/51 (25.5%)13/51 (25.5%)1/51 (2%)
Most frequent serious events
Most frequent serious events
EventAll Participants
DeathGeneral disorders13/51
Most frequent other events
Most frequent other events
EventAll Participants
New metastasis (right scapula)Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/51

Baseline characteristics

Baseline characteristics were assessed in all participants who started the Spinery RF Ablation procedure (N=51) prior to treatment. One participant withdrew consent after enrollment and before treatment allocation and was not included in the baseline analyses.

Age, Categorical
Age, Categorical(Participants)BaseLine
<=18 years0
Between 18 and 65 years24
>=65 years27
Sex: Female, Male
Sex: Female, Male(Participants)BaseLine
Female31
Male20
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)BaseLine
Primary Tumor Site
Primary Tumor Site(participants)BaseLine
Breast19
Lungs12
Prostate4
Bladder1
Kidney4
Colon1
Lynphatic system1
Lymphomas1
Sarcoma1
Adeno Carcinoma1
Intestine1
Chest1
Liver1
Pancreas1
Other1
Target Lesion Location
Target Lesion Location(Participants)BaseLine
Vertebral Body27
Sacrum10
Iliac Crest7
Pari-acetabulum7
Pain Score at Baseline (BPI)
Pain Score at Baseline (BPI)(units on a scale)BaseLine
Mean7.8 ± 1.6
EQ-5D-5L
EQ-5D-5L(units on a scale)BaseLine
Mean42.8 ± 16.8
08

Study locations

5 sites
  • Ospedale Santissima Trinità
    Cagliari, Italy
  • Istituto Oncologico del Mediterraneo IOM
    Catania, Italy
  • Azienda Ospedaliera di Cosenza
    Cosenza, Italy
  • Azienda Ospedaliera Antonio Cardarelli
    Naples, Italy
  • Azienda Ospedaliera Universitaria Senese
    Siena, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Feb 2024, 19 months.

Results were first posted in Nov 2025, 1 year 9 months after primary completion.

Of 320 interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 91. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2022
First posted
Jul 20, 2022
StartActual
Jul 11, 2022
Primary completionActual
Feb 15, 2024
CompletionActual
Nov 30, 2024
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05467540
Lead sponsor
Axon srl
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Jul 11, 2022
Primary completion
Feb 15, 2024
Completion
Nov 30, 2024
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Study contacts

Mario Muto, Prof, MD
study director · Azienda Ospedaliera Antonio Cardarelli, Naples, Italy
Stefano Marini, MD
principal investigator · Ospedale Santissima Trinità, Cagliari, Italy
Francesco Amato, MD
principal investigator · Azienda Ospedaliera di Cosenza, Cosenza, Italy
Luigi Manfrè, MD
principal investigator · Istituto Oncologico del Mediterraneo, Catania, Italy
Matteo Bellini, MD
principal investigator · Azienda Ospedaliera Universitaria Senese, Siena, Italy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion